• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4598788)   Today's Articles (9727)   Subscriber (49356)
Number Citation Analysis
51
Broutin S, Dupuy A, Koscielny S, Fataccioli V, Lemonnier F, de Leval L, Robe C, Pujals A, Safar V, Delarue R, Delfau-Larue M, Ribrag V, Haioun C, Gaulard P, Paci A. SERUM 2-HYDROXYGLUTARATE, A PREDICTIVE BIOMARKER OF THE PRESENCE OF IDH2 MUTATIONS IN AITL PATIENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
52
Michot J, Camara-Clayette V, Chahine C, Lazarovici J, Bosq J, Ghez D, Dartigues P, Danu A, Arfi-Rouche J, Tselikas L, Ba B, Cotteret S, Rahali W, Vergé V, Ribrag V. Molecular landscape of relapse/refractory diffuse large B-cell lymphoma. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
53
Zinzani P, Ribrag V, Moskowitz C, Michot J, Kuruvilla J, Bartlett N, Balakumaran A, Chatterjee A, Chlosta S, Shipp M, Armand P. PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE-013 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_50] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
54
Michot J, Bouabdallah R, Doorduijn J, Vitolo U, Chiappella A, Kersten M, Zinzani P, Sarmiento R, Mosulen S, Petrarca M, Pourdehnad M, Hege K, Yang Z, Nikolova Z, Ribrag V. PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
55
Zinzani P, Kline J, Chen R, Ribrag V, Salles G, Matsumura I, Zhu Y, Ricart A, Balakumaran A, Fanale M. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw525.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
56
Michot JM, Armand P, Ding W, Ribrag V, Christian B, Marinello P, Chlosta S, Zhang Y, Shipp M, Zinzani P. KEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw525.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
57
Fanale M, Kline J, Chen R, Ribrag V, Salles G, Matsumura I, Zhu Y, Ricart A, Balakumaran A, Zinzani P. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.42] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
58
Boros A, Lazarovici J, Danu A, Michot J, Beaudré A, Arfi-Rouche J, Ghez D, Bosq J, Ribrag V, Mazeron R. Faut-il irradier le scrotum des patients atteints d’un lymphome testiculaire primitif ? Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
59
Bigot F, Alvarez EC, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Gazzah A, Bonnet C, Michot JM, Marabelle A, Soria JC, Massard C. Identification of new prognostic factors in phase I patients treated by immunotherapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
60
Michot JM, Armand P, Ding W, Ribrag V, Christian B, Balakumaran A, Marinello P, Chlosta S, Zhang Y, Shipp M, Zinzani P. Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.39] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
61
Michot JM, Benajiba L, Baldini C, Faivre L, Danu A, Hollebecque A, Massard C, Varga A, Bahleda R, Gazzah A, Soria JC, Ribrag V. Outcome of patients with relapsed/refractory lymphoma in a large cohort inside a phase 1 clinic department. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv090.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
62
Ribrag V, Soria JC, Reyderman L, Chen R, Salazar P, Kumar N, Kuznetsov G, Keilhack H, Ottesen L, Italiano A. Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv085.2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
63
Ribrag V, Soria J, Reyderman L, Chen R, Salazar P, Kumar N, Kuznetsov G, Keilhack H, Ottesen L, Italiano A. 6LBA Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70727-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
64
Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 2014;29:249-52. [DOI: 10.1038/leu.2014.270] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
65
Camara-Clayette V, Lecluse Y, Schrader C, Klapper W, Vainchenker W, Hermine O, Ribrag V. The NF-κB pathway is rarely spontaneously activated in mantle cell lymphoma (MCL) cell lines and patient's samples. Eur J Cancer 2013;50:159-69. [PMID: 24135685 DOI: 10.1016/j.ejca.2013.09.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Revised: 09/15/2013] [Accepted: 09/16/2013] [Indexed: 12/22/2022]
66
Chen DS, Feltquate DM, Smothers F, Hoos A, Langermann S, Marshall S, May R, Fleming M, Hodi FS, Senderowicz A, Wiman KG, de Dosso S, Fiedler W, Gianni L, Cresta S, Schulze-Bergkamen HB, Gurrieri L, Salzberg M, Dietrich B, Danielczyk A, Baumeister H, Goletz S, Sessa C, Strumberg D, Schultheis B, Santel A, Gebhardt F, Meyer-Sabellek W, Keil O, Giese K, Kaufmann J, Maio M, Choy G, Covre A, Parisi G, Nicolay H, Fratta E, Fonsatti E, Sigalotti L, Coral S, Taverna P, Azab M, Deutsch E, Lepechoux C, Pignon JP, Tao YT, Rivera S, Bourgier BC, Angokai M, Bahleda R, Slimane K, Angevin E, Besse BB, Soria JC, Dragnev K, Beumer JH, Anyang B, Ma T, Galimberti F, Erkmen CP, Nugent W, Rigas J, Abraham K, Johnstone D, Memoli V, Dmitrovsky E, Voest EE, Siu L, Janku F, Soria JC, Tsimberidou A, Kurzrock R, Tabernero J, Rodon J, Berger R, Onn A, Batist G, Bresson C, Lazar V, Molenaar JJ, Koster J, Ebus M, Zwijnenburg DA, van Sluis P, Lamers F, Schild L, van der Ploeg I, Caron HN, Versteeg R, Pouyssegur J, Marchiq I, Chiche J, Roux D, Le Floch R, Critchlow SE, Wooster RF, Agresta S, Yen KE, Janne PA, Plummer ER, Trinchieri G, Ellis L, Chan SL, Yeo W, Chan AT, Mouliere F, El Messaoudi S, Gongora C, Lamy PJ, del Rio M, Lopez-Crapez E, Gillet B, Mathonnet M, Pezet D, Ychou M, Thierry AR, Ribrag V, Vainchenker W, Constantinescu S, Keilhack H, Umelo IA, Noeparast A, Chen G, Renard M, Geers C, Vansteenkiste J, Teugels E, de Greve J, Rixe O, Qi X, Chu Z, Celerier J, Leconte L, Minet N, Pakradouni J, Kaur B, Cuttitta F, Wagner AJ, Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Demetri GD, Weng S, Debussche L, Agoni L, Reddy EP, Guha C, Silence K, Thibault A, de Haard H, Dreier T, Ulrichts P, Moshir M, Gabriels S, Luo J, Carter C, Rajan A, Khozin S, Thomas A, Lopez-Chavez A, Brzezniak C, Doyle L, Keen C, Manu M, Raffeld M, Giaccone G, Lutzker S, Melief JM, Eckhardt SG, Trusolino L, Migliardi G, Zanella ER, Cottino F, Galimi F, Sassi F, Marsoni S, Comoglio PM, Bertotti A, Hidalgo M, Weroha SJ, Haluska P, Becker MA, Harrington SC, Goodman KM, Gonzalez SE, al Hilli M, Butler KA, Kalli KR, Oberg AL, Huijbers IJ, Bin Ali R, Pritchard C, Cozijnsen M, Proost N, Song JY, Krimpenfort P, Michalak E, Jonkers J, Berns A, Banerji U, Stewart A, Thavasu P, Banerjee S, Kaye SB. Lectures. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
67
Ribrag V. Hematology and Drug Development in the 'Targeted Therapy' Area. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt042.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
68
Danu A, Chalumeau L, Ribrag V, de Botton S, Said Mahmmod S, Blot F, Ghez D, Chalumeau N, Bienvenu B. Un diagnostic qui aura pris du temps. Rev Med Interne 2013;34:57-60. [DOI: 10.1016/j.revmed.2012.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Accepted: 07/01/2012] [Indexed: 12/31/2022]
69
Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367:520-31. [PMID: 22873532 DOI: 10.1056/nejmoa1200920] [Citation(s) in RCA: 361] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
70
Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F, Pramod R, Bahleda R, Deutsch E, Bourgier C, Angevin E, Lazar V, Ribrag V, Koscielny S, Chami L, Lassau N, Dromain C, Robert C, Routier E, Armand JP, Soria JC. Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann Oncol 2012;23:1301-1306. [PMID: 21917737 DOI: 10.1093/annonc/mdr383] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023]  Open
71
Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E, Vainchenker W, Plo I. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012;31:1323-33. [PMID: 21785463 DOI: 10.1038/onc.2011.313] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2011] [Revised: 06/17/2011] [Accepted: 06/18/2011] [Indexed: 01/10/2023]
72
Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. RBC-transfusion guidelines update. Leuk Res 2012;36:659-60. [PMID: 22336392 DOI: 10.1016/j.leukres.2012.01.023] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2012] [Revised: 01/13/2012] [Accepted: 01/23/2012] [Indexed: 12/22/2022]
73
Canioni D, Deau B, Bachy E, Ribrag V, Delarue R, Rubio M, Bosq J, Vasiliu V, Bruneau J, Varet B, Brousse N, Hermine O. Le pourcentage de macrophages et le nombre des mastocytes et lymphocytes TiA1+sont des biomarqueurs du caractère réfractaire primaire ou d’une rechute précoce dans les lymphomes de Hodgkin classiques. Ann Pathol 2011. [DOI: 10.1016/j.annpat.2011.09.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
74
Paumier A, Galibafian M, Gilmore J, Hanna C, Raphaël J, Ferme C, Ribrag V, Girinsky T. Optimisation de la radiothérapie « involved-node » grâce à l’inspiration profonde bloquée dans la maladie de Hodgkin supradiaphragmatique. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
75
Paumier A, Ghalibafian M, Gilmore J, Hanna C, Raphaël J, Ferme C, Ribrag V, Girinsky T. Évaluation de la radiothérapie faible (deux séances de 2Gy) à visée curative dans le lymphome du Malt pulmonaire. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
PrevPage 3 of 6 123456Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA